{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T03:24:13Z","timestamp":1775791453109,"version":"3.50.1"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2024,10,15]],"date-time":"2024-10-15T00:00:00Z","timestamp":1728950400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,10,15]],"date-time":"2024-10-15T00:00:00Z","timestamp":1728950400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001794","name":"The University of Queensland","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001794","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Surviv"],"published-print":{"date-parts":[[2026,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>To identify the number and timing of audiology encounters for adult oncology patients in a tertiary care setting in Australia.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Setting (population)<\/jats:title>\n                    <jats:p>A retrospective case review was completed for 149 patients who received Cisplatin chemotherapy (CT) at a large, publicly funded tertiary hospital in Brisbane, Queensland, Australia between 1st January and 31st December 2019. Patient data was extracted from the Queensland Oncology Repository (QOR) provided by Cancer Alliance Queensland (CAQ).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The number of audiology encounters was low overall with a median of 0 and interquartile range (IQR) of 0\u20131. Of the entire patient cohort, there was a mean of 1.2 encounters with 56% of patients not engaging with audiology. Where audiology did occur, encounters were most likely before or early in the CT treatment period.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This study has demonstrated engagement with audiology services for patients undergoing CT treatment was limited with the few audiology engagements occurring before or early in the CT treatment period. Further research is needed to identify the barriers and facilitators to accessing audiological ototoxic monitoring (OtoM) during chemotherapy treatment in hospitals in Australia.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Implications for cancer survivors<\/jats:title>\n                    <jats:p>Early identification of ototoxic hearing loss offers the opportunity to minimise further exposure to the ototoxic agent, minimise functional and communication impacts for the patient and provide early opportunity for discussion, education and counselling with patients, carers and their treating team. This, in turn, is expected to improve health related quality of life.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s11764-024-01689-x","type":"journal-article","created":{"date-parts":[[2024,10,14]],"date-time":"2024-10-14T22:01:53Z","timestamp":1728943313000},"page":"816-822","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["A retrospective audit of audiology encounters in patients undergoing Cisplatin treatment at a large Australian tertiary cancer care centre"],"prefix":"10.1007","volume":"20","author":[{"given":"Georgia M.","family":"Lester","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wayne J.","family":"Wilson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbra H. B.","family":"Timmer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rahul M.","family":"Ladwa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,10,15]]},"reference":[{"issue":"2","key":"1689_CR1","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1007\/s00280-019-04012-z","volume":"85","author":"DM Baguley","year":"2020","unstructured":"Baguley DM, Prayuenyong P. Looking beyond the audiogram in ototoxicity associated with platinum-based chemotherapy. Cancer Chemother Pharmacol. 2020;85(2):245\u201350. https:\/\/doi.org\/10.1007\/s00280-019-04012-z.","journal-title":"Cancer Chemother Pharmacol"},{"key":"1689_CR2","unstructured":"American Speech-Language Hearing Association, Audiologic management of individuals receiving cochleotoxic drug therapy: American Speech-Language Hearing Association, 1994. [Online]. Available: https:\/\/www.asha.org\/policy\/gl1994-00003\/. Accessed 21 Jan 2022."},{"key":"1689_CR3","unstructured":"American Academy of Audiology, \u201cPosition statement and clinical practice guidelines: ototoxicity monitoring.\u201d [Online]. Available: https:\/\/audiology-web.s3.amazonaws.com\/migrated\/OtoMonGuidelines.pdf_539974c40999c1.58842217.pdf. Accessed 21 Jan 2022."},{"key":"1689_CR4","unstructured":"Health Professionals Council of South Africa, \u201cGuidelines for the audiological management of patients on treatment that includes ototoxic medications.\u201d 2018. [Online]. Available: https:\/\/www.hpcsa.co.za\/Uploads\/SLH\/Guidelines%20for%20Audiological%20Management%20of%20Patients%20on%20Treatment%20that%20includes%20Ototoxic%20Medications.pdf. Accessed 23 Jan 2022."},{"issue":"1398","key":"1689_CR5","first-page":"84","volume":"127","author":"L Steffens","year":"2014","unstructured":"Steffens L, Venter K, O\u2019Beirne GA, Kelly-Campbell R, Gibbs D, Bird P. \u201cThe current state of ototoxicity monitoring in New Zealand\u201d, (in eng). N Z Med J. 2014;127(1398):84\u201397.","journal-title":"N Z Med J"},{"key":"1689_CR6","unstructured":"M. Dille, \u201cBarriers and potential solutions to increase the success of ototoxicity monitoring. American Speech-Language Hearing Association. 2018. [Online]. Available: https:\/\/www.asha.org\/articles\/barriers-and-potential-solutions-to-increase-the-success-of-ototoxicity-monitoring-programs\/. Accessed 14 Feb 2024."},{"key":"1689_CR7","doi-asserted-by":"publisher","unstructured":"K. Ehlert, B. Heinze, and D. W. Swanepoel, \u201cOtotoxicity monitoring in South African cancer facilities: a national survey,\u201d South African J Comm Disorders. 2022;69 1. https:\/\/doi.org\/10.4102\/sajcd.v69i1.846.","DOI":"10.4102\/sajcd.v69i1.846"},{"issue":"sup4","key":"1689_CR8","doi-asserted-by":"publisher","first-page":"S29","DOI":"10.1080\/14992027.2018.1460495","volume":"57","author":"D Maru","year":"2018","unstructured":"Maru D, Malky G-A. Current practice of ototoxicity management across the United Kingdom (UK). Int J Audiol. 2018;57(sup4):S29\u201341. https:\/\/doi.org\/10.1080\/14992027.2018.1460495.","journal-title":"Int J Audiol"},{"issue":"3","key":"1689_CR9","doi-asserted-by":"publisher","first-page":"171","DOI":"10.4103\/jpbs.JPBS_17_17","volume":"9","author":"K Khoza-Shangase","year":"2017","unstructured":"Khoza-Shangase K. Risk versus benefit: who assesses this in the management of patients on ototoxic drugs? J Pharm Bioall Sci, Rev Article. 2017;9(3):171\u20137. https:\/\/doi.org\/10.4103\/jpbs.JPBS_17_17.","journal-title":"J Pharm Bioall Sci, Rev Article"},{"issue":"sup4","key":"1689_CR10","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1080\/14992027.2017.1398421","volume":"57","author":"D Konrad-Martin","year":"2018","unstructured":"Konrad-Martin D, et al. Applying U.S. national guidelines for ototoxicity monitoring in adult patients: perspectives on patient populations, service gaps, barriers and solutions. Int J Audiol. 2018;57(sup4):S3\u201318. https:\/\/doi.org\/10.1080\/14992027.2017.1398421.","journal-title":"Int J Audiol"},{"issue":"3","key":"1689_CR11","doi-asserted-by":"publisher","first-page":"268","DOI":"10.3390\/toxics3030268","volume":"3","author":"A Callejo","year":"2015","unstructured":"Callejo A, Sed\u00f3-Cabez\u00f3n L, Juan I, Llorens J. Cisplatin-induced ototoxicity: effects, mechanisms and protection strategies. Toxics. 2015;3(3):268\u201393. https:\/\/doi.org\/10.3390\/toxics3030268.","journal-title":"Toxics"},{"key":"1689_CR12","unstructured":"Cancer Alliance Queensland. \u201cData and access.\u201d Cancer Alliance Queensland. https:\/\/cancerallianceqld.health.qld.gov.au\/our-data\/ (accessed 2024)."},{"key":"1689_CR13","unstructured":"Queensland Government, \u201cHealth equity and access.\u201d [Online]. Available: https:\/\/metrosouth.health.qld.gov.au\/health-equity-and-access\/culturally-and-linguistically-diverse-cald-people. Accessed 12 Sept 2023."},{"key":"1689_CR14","unstructured":"Queensland Government, \u201cPrincess Alexandra Hospital.\u201d [Online]. Available: https:\/\/metrosouth.health.qld.gov.au\/princess-alexandra-hospital. Accessed 10 Sept\u00a0 2023."},{"issue":"sup4","key":"1689_CR15","doi-asserted-by":"publisher","first-page":"S48","DOI":"10.1080\/14992027.2017.1353710","volume":"57","author":"NC Schmitt","year":"2018","unstructured":"Schmitt NC, Page BR. Chemoradiation-induced hearing loss remains a major concern for head and neck cancer patients. Int J Audiol. 2018;57(sup4):S48\u201353. https:\/\/doi.org\/10.1080\/14992027.2017.1353710.","journal-title":"Int J Audiol"},{"key":"1689_CR16","unstructured":"N. C. Institute, \u201cOral complications of chemotherpay and head\/neck cancer radiation,\u201d April 26, 2019. [Online]. Available: https:\/\/www.cancer.gov\/about-cancer\/treatment\/side-effects\/mouth-throat\/oral-complications-pdq"},{"issue":"1","key":"1689_CR17","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1186\/s12967-021-03144-2","volume":"19","author":"MG Cristofaro","year":"2021","unstructured":"Cristofaro MG, et al. The health risks of dysphagia for patients with head and neck cancer: a multicentre prospective observational study. J Transl Med. 2021;19(1):472\u2013472. https:\/\/doi.org\/10.1186\/s12967-021-03144-2.","journal-title":"J Transl Med"},{"issue":"4","key":"1689_CR18","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1007\/s11764-018-0687-7","volume":"12","author":"SL Crowder","year":"2018","unstructured":"Crowder SL, Douglas KG, Yanina Pepino M, Sarma KP, Arthur AE. Nutrition impact symptoms and associated outcomes in post-chemoradiotherapy head and neck cancer survivors: a systematic review. J Cancer Surviv. 2018;12(4):479\u201394. https:\/\/doi.org\/10.1007\/s11764-018-0687-7.","journal-title":"J Cancer Surviv."},{"issue":"1","key":"1689_CR19","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s13104-020-05440-4","volume":"14","author":"TA Yifru","year":"2021","unstructured":"Yifru TA, Kisa S, Dinegde NG, Atnafu NT. Dysphagia and its impact on the quality of life of head and neck cancer patients: institution-based cross-sectional study. BMC Res Notes. 2021;14(1):11\u201311. https:\/\/doi.org\/10.1186\/s13104-020-05440-4.","journal-title":"BMC Res Notes"},{"issue":"2","key":"1689_CR20","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1002\/pon.635","volume":"12","author":"PA Parker","year":"2003","unstructured":"Parker PA, Baile WF, Moor CD, Cohen L. Psychosocial and demographic predictors of quality of life in a large sample of cancer patients. Psycho-Oncology. 2003;12(2):183\u201393. https:\/\/doi.org\/10.1002\/pon.635.","journal-title":"Psycho-Oncology"},{"issue":"4","key":"1689_CR21","doi-asserted-by":"publisher","first-page":"E14","DOI":"10.1097\/NCC.0b013e31822fc76c","volume":"35","author":"L Anguiano","year":"2012","unstructured":"Anguiano L, Mayer DK, Piven ML, Rosenstein D. A literature review of suicide in cancer patients. Cancer Nurs. 2012;35(4):E14\u201326. https:\/\/doi.org\/10.1097\/NCC.0b013e31822fc76c.","journal-title":"Cancer Nurs"},{"issue":"5","key":"1689_CR22","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1159\/000446991","volume":"85","author":"S Kuhnt","year":"2016","unstructured":"Kuhnt S, et al. Twelve-month and lifetime prevalence of mental disorders in cancer patients. Psychother Psychosom. 2016;85(5):289\u201396. https:\/\/doi.org\/10.1159\/000446991.","journal-title":"Psychother Psychosom"},{"key":"1689_CR23","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1007\/978-3-030-84702-9_19","volume-title":"Handbook of quality of life in cancer","author":"M Zacharia","year":"2022","unstructured":"Zacharia M, Karekla M. Handbook of quality of life in cancer. Cham: Springer International Publishing; 2022. p. 311\u201337."}],"container-title":["Journal of Cancer Survivorship"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11764-024-01689-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11764-024-01689-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11764-024-01689-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T17:01:24Z","timestamp":1773507684000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11764-024-01689-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,15]]},"references-count":23,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["1689"],"URL":"https:\/\/doi.org\/10.1007\/s11764-024-01689-x","relation":{},"ISSN":["1932-2259","1932-2267"],"issn-type":[{"value":"1932-2259","type":"print"},{"value":"1932-2267","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,15]]},"assertion":[{"value":"23 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 September 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 October 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethics approval was received from Metro South Human Research Ethics Committee (HREC)(HREC\/2022\/QMS\/99194) and the University of Queensland (2022\/HE002149) prior to commencement of the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"All patients consented to the use of their deidentified data for research purposes at the time of their treatment.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"All patients consented to the publication of their deidentified data for any future research papers or presentations at the time of their treatment.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}